SCHEMBL1666989

SCHEMBL1666989

CC(C)CNc1[c]cccc1

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.40
ESR1 P03372 6/20 0.35
ACP1 P24666 1/20 0.35
TLR7 Q9NYK1 2/20 0.33
KMT2A Q03164 2/20 0.33
MAPT P10636 2/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
KDM4E B2RXH2 1/20 0.33
GAA P10253 1/20 0.33
LMNA P02545 1/20 0.33
ALDH1A1 P00352 2/20 0.33
MEN1 O00255 1/20 0.33
ESR2 Q92731 1/20 0.32
IDH1 O75874 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP2C19 P33261 1/20 0.32
HRH4 Q9H3N8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8667048 0.81 CYP1A2 (0.41) MAPTL3MBTL1KDM4ELMNAALDH1A1
SCHEMBL2449378 0.80 SMN1; SMN2 (0.32)
SCHEMBL8664655 0.78 CYP1A2 (0.33) KMT2AMAPTL3MBTL1LMNAALDH1A1
SCHEMBL1665147 0.77 IDO1 (0.39) IDO1ESR1ACP1TLR7KMT2A
SCHEMBL343994 0.77
SCHEMBL8666664 0.77 CYP1A2 (0.33) KMT2AMAPTL3MBTL1LMNAALDH1A1
SCHEMBL8668377 0.74 LMNA (0.54) KMT2AMAPTL3MBTL1GAALMNA
SCHEMBL2182651 0.73 IDO1 (0.38) IDO1TLR7KMT2AL3MBTL1KDM4E
SCHEMBL1664327 0.73 ESR1 (0.35) IDO1ESR1HRH4
SCHEMBL5472820 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2231602-A1 GAMMA SECRETASE MODULATORS Amgen, Inc (US) 2010-09-29 EP claimed
WO-2009075874-A1 GAMMA SECRETASE MODULATORS AMGEN INC. (US) 2009-06-18 WO claimed
US-8022072-B2 Azolylmethylidenehydrazine derivative and use thereof KAKEN PHARMACEUTICAL CO., LTD. (JP) 2011-09-20 US disclosed
US-20110166132-A1 Gamma Secretase Modulators AMGEN INC. (US) 2011-07-07 US disclosed
US-7968019-B2 Optical compensation film, method for producing optical compensation film, polarization plate and liquid crystal display KONICA MINOLTA OPTO, INC. (JP) 2011-06-28 US disclosed
US-7922947-B2 Method of producing dispersion FUJIFILM CORPORATION (JP) 2011-04-12 US disclosed
EP-2231602-A1 GAMMA SECRETASE MODULATORS Amgen, Inc (US) 2010-09-29 EP disclosed
US-20100190754-A1 AZOLYLMETHYLIDENEHYDRAZINE DERIVATIVE AND USE THEREOF KAKEN PHARMACEUTICAL CO., LTD. (JP) 2010-07-29 US disclosed
EP-2168951-A1 AZOLYLMETHYLENEHYDRAZINE DERIVATIVE AND USE THEREOF KAKEN PHARMACEUTICAL CO., LTD. (JP) 2010-03-31 EP disclosed
WO-2009075874-A1 GAMMA SECRETASE MODULATORS AMGEN INC. (US) 2009-06-18 WO disclosed
US-7166339-B1 Phase contrast plate comprising one sheet of cellulose ester film containing aromatic compound FUJIFILM CORPORATION (JP) 2007-01-23 US disclosed
US-20060216437-A1 Optical compensation film, method for producing optical compensation film, polarization plate and liquid crystal display KONICA MINOLTA OPTO, INC. (JP) 2006-09-28 US disclosed
US-20050062193-A1 Method of producing dispersion FUJIFILM CORPORATION (JP) 2005-03-24 US disclosed
CN-1173198-C Phase retardation plate comprising cellulose ester film, circularly polarizing plate and liquid crystal display device 富士胶片株式会社 2004-10-27 CN disclosed
EP-1425283-A1 NOVEL 4-AMINOFUROPYRIMIDINES AND THE USE THEREOF Bayer HealthCare AG (DE) 2004-06-09 EP disclosed
US-6630973-B1 Compensatory sheet, ellipsoidal polarizing plate and liquid crystal display. FUJI PHOTO FILM CO., LTD. (JP) 2003-10-07 US disclosed
WO-2003018589-A1 NOVEL 4-AMINOFUROPYRIMIDINES AND THE USE THEREOF BAYER HEALTHCARE AG (DE) 2003-03-06 WO disclosed
EP-1182470-A1 PHASE CONTRAST PLATE COMPRISING ONE SHEET OF CELLULOSE ESTER FILM CONTAINING AROMATIC COMPOUND FUJI PHOTO FILM CO., LTD. (JP) 2002-02-27 EP disclosed
US-5750552-A ANTIULCER AGENTS ARAX CO., LTD. (JP) 1998-05-12 US disclosed
EP-0736527-A1 Imadazoline derivative, possible tautomer thereof, process of manufacturing therefor, and vulnerary including such derivative or tautomer ARAX CO., LTD. (JP) 1996-10-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166132-A1 Gamma Secretase Modulators BACE1, BACE2, PSEN1 IDO1 4594/4885ESR1 1949/4885ACP1 942/4885
US-20100190754-A1 AZOLYLMETHYLIDENEHYDRAZINE DERIVATIVE AND USE THEREOF ARSA, AHR, HRH2 IDO1 10/4885ESR1 2315/4885ACP1 3960/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.